GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Marvel Biosciences MRVL.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.12

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Marvel Biosciences

Its shares trade on TSX Venture under the ticker MRVL.V. It has been listed since 28 February 2019.

Marvel Biosciences Corp. Is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a novel fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
28 Feb 2019

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Marvel Biosciences Corp. utilizes drug redevelopment for neurological diseases with MB-204 in clinical trials.
  • The company develops synthetic derivatives of off-patent drugs for new disease indications.
  • Marvel Biotechnology Inc. supports the firm's research and development activities.

Weaknesses

  • The company's lead compound MB-204 is focused on depression and Alzheimer's disease only.
  • Marvel Biosciences Corp. has no current commercial products on the market.
  • The firm's development stage limits immediate revenue generation.

Opportunities

  • MB-204 shows potential for treating NASH liver fibrosis in clinical trials.
  • The company can expand into new neurological disease indications beyond current focus.
  • Collaborations with pharmaceutical companies could accelerate drug development.

Threats

  • Competition from other biotech firms developing similar drug derivatives.
  • Regulatory approval delays could impact clinical trial timelines.
  • Market competition in the neurological disease treatment sector remains high.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.